Inhibiting IGF2-TMED10 Interaction to Block Secretion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for inhibiting IGF2 signaling, such as targeting the IGF1 receptor, have limitations in effectively blocking the secretion of newly synthesized IGF2, which is crucial for treating cancers associated with abnormal IGF2 signaling.
Innovation Solution
A pharmaceutical composition that inhibits the IGF2-TMED10 interaction, using an inhibitor that can be a human IGF2 polypeptide, a human TMED10 polypeptide, a small molecule, a covalent inhibitor, an antibody, or a genome editing tool, to block the secretion of IGF2 in cells with abnormal IGF2 signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IGF1R inhibitors are used to inhibit IGF2 signaling, then anti-tumor effects are demonstrated, but the secretion of newly synthesized IGF2 is not effectively blocked
Solution Approach 1:
The patent extracts and targets the specific secretion mechanism of IGF2 by identifying TMED10 as the cargo receptor responsible for IGF2 export from the ER. By taking out and blocking this specific interaction between TMED10 and IGF2, the patent directly prevents the secretion of newly synthesized IGF2, addressing the limitation of IGF1R inhibitors that fail to block IGF2 secretion effectively.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that specifically bind to the TMED10-IGF2 interaction interface. These intermediary compounds block the cargo receptor TMED10 from recognizing and transporting IGF2, thereby preventing IGF2 secretion without affecting IGF1R signaling directly. This intermediary approach resolves the contradiction by targeting the upstream secretion mechanism rather than the downstream receptor.
2Reliability
If IGF2 signaling is inhibited by targeting receptors, then downstream signaling is blocked, but the upstream secretion mechanism remains active
Solution Approach 1:
The patent applies preliminary action by blocking IGF2 secretion at the ER exit stage before the protein enters the secretory pathway. By using small molecule compounds to prevent TMED10-mediated export of IGF2 from the ER, the patent stops IGF2 from reaching the cell surface and activating receptors in the first place. This preliminary intervention simplifies the approach by preventing the problem at its source rather than dealing with complex downstream receptor signaling pathways.
3Loss of substance
If the TMED10-IGF2 interaction is blocked, then IGF2 secretion is prevented, but the complexity of the inhibition mechanism increases
Solution Approach 1:
The patent replaces the complex biological mechanical system of protein-protein interaction (TMED10-IGF2) with a simpler small molecule compound-based inhibition system. The small molecule compounds act as steric blockers that physically prevent the TMED10-IGF2 interaction without requiring complex cellular machinery or genetic modification. This substitution simplifies the inhibition mechanism while effectively blocking IGF2 secretion.
Data Source
AI summary
The subject invention pertains to compositions and methods for inhibiting IGF2 signaling. Insulin-like growth factor 2 (IGF2) is a key signaling molecule that plays important roles in various physiological processes, including skeletal myogenesis during development and adult muscle remodeling. Abnormal activation of the signaling pathway induced by IGF2 has been shown to promote cancer progression. TMED10, a p24 family protein, functions as a cargo receptor, promoting the export of IGF2 from the endoplasmic reticulum (ER) via recognizing an ER export signal on IGF2. Moreover, TMED10 also mediates ER export of sortilin, which is important to regulate the export of IGF2 from the trans-Golgi network. The subject invention features a novel therapeutic strategy for cancer treatment, that includes, but is not limited to, inhibitors targeting the interaction between IGF2 and TMED10.